The Most Undertreated Problem in Menopause: Genitourinary Symptoms and Topical Oestrogen

Of all the symptoms the menopause brings, one stands out for an unhappy reason: it is among the most common, it almost never gets better on its own, and it is one of the few that responds reliably to a simple treatment — yet it is the one women are least likely to mention. Hot flushes get talked about, joked about, written about. Vaginal dryness, urinary urgency, pain during sex and recurrent water infections are discussed in a near-total silence, raised at perhaps one consultation in four where they exist.

The silence has consequences. Because nobody mentions it, nobody treats it, and because it is one of the few menopausal symptoms that tends to worsen rather than fade with time, that untreated silence stretches over years. This is a problem worth dragging into the open, partly because it is so common, and partly because the treatment is so much better than most women realise.

What genitourinary syndrome of menopause actually is

The clinical term — genitourinary syndrome of menopause, or GSM — replaced the older and narrower "vaginal atrophy" precisely because the problem is broader than the vagina. As oestrogen falls, the tissues of the vulva, vagina, urethra and bladder, all of which are rich in oestrogen receptors, become thinner, drier, less elastic and less well supplied with blood. The local environment changes too: the natural acidity that keeps the vaginal microbiome healthy shifts, which makes infections more likely.

The result is a cluster of symptoms that often arrive together: vaginal dryness, itching or burning, discomfort or pain during sex, and on the urinary side, urgency, frequency, discomfort passing urine, and recurrent urinary tract infections. In older women, recurrent UTIs are frequently driven by this underlying tissue change, which is one reason the syndrome matters well beyond the bedroom.

Why it doesn't get better on its own

This is the part that distinguishes GSM from much of the rest of the menopausal picture. Hot flushes and night sweats, troublesome as they are, tend to settle over a number of years as the body adjusts. GSM does the opposite. It reflects an ongoing tissue change driven by a sustained low-oestrogen state, and without treatment it typically persists indefinitely and often progresses. Waiting it out is not a strategy; there is nothing to wait for.

That single fact reframes the whole thing. A symptom you will otherwise carry for the rest of your life, that quietly erodes comfort, intimacy and urinary health, is worth a conversation — even an awkward one.

The treatment most people haven't heard about

For many women, the most effective treatment for GSM is low-dose oestrogen applied locally — to the vagina itself — as a cream, pessary, gel or vaginal ring. And here is the crucial point that resolves most of the fear around it: this is not the same as taking HRT.

Topical vaginal oestrogen is designed to act on the local tissue, restoring its thickness, elasticity, blood supply and natural acidity. At the low doses used, systemic absorption — the amount that reaches the rest of the body through the bloodstream — is minimal. Blood oestrogen levels generally remain within the normal postmenopausal range. This is the central reason its safety profile differs so markedly from systemic HRT: it is, in effect, a local treatment for a local problem.

Because of that, the considerations that complicate the systemic HRT conversation — the breast cancer and clot discussions of that other article — apply quite differently here. UK and specialist guidance reflects this: low-dose vaginal oestrogen is regarded as safe for the great majority of postmenopausal women, can be used long term (the symptoms return if it is stopped, since the underlying tissue change persists), and does not require the addition of a progestogen for womb protection in the way systemic oestrogen does, because so little reaches the womb lining. Women with a history of breast cancer are a group where the decision is more individual and best made with their specialist — a genuine nuance, not a blanket prohibition.

There are also non-hormonal options worth knowing about. Vaginal moisturisers, used regularly, and lubricants, used during sex, can ease symptoms and are a reasonable first step or a useful addition — particularly for women who prefer to avoid hormones or are waiting to discuss them. They manage symptoms rather than reversing the underlying tissue change, but for milder cases they may be enough.

The red flag that overrides everything

There is one symptom in this territory that is never to be assumed away as "just dryness" or "just the menopause": bleeding after the menopause.

Any vaginal bleeding that occurs more than twelve months after a woman's last period — postmenopausal bleeding — needs medical assessment. In most cases the cause turns out to be benign, including the fragile tissues of GSM itself. But postmenopausal bleeding is also the cardinal symptom of endometrial (womb) cancer, and it cannot be distinguished from a harmless cause without proper assessment. This holds regardless of whether a woman is using vaginal oestrogen. The rule is simple and worth stating plainly: new bleeding after the menopause is always a reason to see a doctor, not to wait and see.

Practical takeaways

• Genitourinary syndrome of menopause — dryness, discomfort, urinary urgency, recurrent UTIs — is common, frequently unspoken, and unlike hot flushes does not resolve on its own.
• Low-dose vaginal oestrogen treats the underlying tissue change directly, with minimal systemic absorption and a safety profile quite different from systemic HRT.
• It can generally be used long term, and usually does not require a progestogen, because so little reaches the rest of the body.
• Non-hormonal moisturisers and lubricants are a reasonable option, particularly for milder symptoms or by preference.
• Any bleeding after the menopause needs medical assessment, every time, regardless of any treatment in use.

What this doesn't mean

It doesn't mean every woman needs vaginal oestrogen, or that GSM is dangerous — it is a common, benign tissue change, not a disease. Nor does "minimal systemic absorption" mean "zero," or that the treatment suits absolutely everyone; women with certain histories, breast cancer in particular, have a more individual decision to make. The point is not that the answer is always yes — it is that the option exists, works, and is too often never offered.

When to seek medical advice

Raise genitourinary symptoms with a GP, practice nurse or pharmacist if they are affecting comfort, intimacy or urinary health — they are treatable, and you do not have to live with them. Seek prompt assessment for any bleeding after the menopause, for recurrent urinary infections, or for new pain, and do not let embarrassment be the reason a treatable problem goes untreated.

A closing thought

There is something quietly unjust about a symptom this common being this neglected — undertreated not because the medicine is hard, but because the conversation is. The treatment has been available and well understood for years; what is missing is usually the mention. If this article does one useful thing, let it be to make the next consultation slightly easier to start — and to make clear that the awkwardness is entirely survivable, and the relief on the other side of it well worth the sentence it takes to ask.

Further reading and sources

• NICE NG23 — Menopause: diagnosis and management
• British Menopause Society — guidance on urogenital atrophy and vaginal oestrogen
• Cochrane review — oestrogen for vaginal symptoms in postmenopausal women
• NHS — vaginal dryness and menopause information
• Royal College of Obstetricians and Gynaecologists — patient information on postmenopausal bleeding

Brand names are mentioned for identification only. The author has no commercial relationship with any manufacturer, and nothing here is an advertisement for, or recommendation to obtain, any medicine.